Scynexis announced data demonstrating the potential use of ibrexafungerp as an agent to address multiple serious fungal infections. The collection of data will be presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases, April 13-16, in Amsterdam. Ibrexafungerp, the first representative of a novel family of compounds referred to as “fungerps”, is being developed for oral and intravenous administration and is in clinical development for the treatment of several serious fungal infections. Six presentations will provide additional evidence of antifungal activity of oral ibrexafungerp, including new clinical case studies from the CARES and FURI trials as well as preclinical data. Case studies from the CARES trial, the first study of an investigational agent to treat patients with Candida auris infections, show “favorable” outcomes following treatment with oral ibrexafungerp. Ibrexafungerp shows “strong” clinical activity in difficult-to-treat patients with resistant Candida pathogens in a variety of infections.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.